Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase Ib/2a Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder

NCT04818086 is registered in ClinicalTrials.gov with Virginia Commonwealth University as lead sponsor.

NCT NCT04818086
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04818086 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase Ib/2a Drug-drug Interaction Study of Lemborexant as an Adjunctive Treatment for Buprenorphine/Naloxone for Opioid Use Disorder
Lead sponsor
Virginia Commonwealth University
Phase
Phase 1/2
Overall status
Completed
Start date
May 3, 2021
Completion date
April 20, 2023
Enrollment
18 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

analgesics, drug interaction, opioid use disorder